Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sunil Sharma
AddedMar 31, 2024
UpdatedMay 31, 2026
Sunil Sharma

Sunil Sharma

Co-Founder, Salarius Pharmaceuticals

CrunchbaseLinkedIn

Sunil Sharma's Career

Salarius Pharmaceuticals
Salarius Pharmaceuticals

Houston, TX, US

Co-Founder
Iterion Therapeutics
Iterion Therapeutics

Houston, TX, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sunil Sharma's Career

Salarius Pharmaceuticals
Salarius Pharmaceuticals
Public$51.2M122010Houston, TX, US
Co-Founder

Leadership at Salarius Pharmaceuticals

Paul LammersPaul LammersBoard Member
Arnold C. HanishArnold C. HanishBoard Member
Jennifer CermakJennifer CermakCo-Founder
David ArthurDavid ArthurCEO
Jonathan LieberJonathan LieberBoard Member
Bill McVicarBill McVicarBoard Member

Similar to Salarius Pharmaceuticals

Saladax BiomedicalSaladax BiomedicalBethlehem, PA, USTherapeuticsest. 2004Saladax BiomedicalBethlehem, PA, US · est. 2004

Saladax Biomedical, a Pennsylvania-based medical firm, specializes in developing oncology therapeutics.

Angel · $54.9M26
Salix PharmaceuticalsSalix PharmaceuticalsRaleigh, NC, USGI Treatments, Pharmaceuticalsest. 1989Salix PharmaceuticalsRaleigh, NC, US · est. 1989

Salix Pharmaceuticals: A US-based specialty pharma company, innovating gastrointestinal treatments.

Public · $750M750
Syndax PharmaceuticalsSyndax PharmaceuticalsWaltham, MA, USCancer Therapiesest. 2005Syndax PharmaceuticalsWaltham, MA, US · est. 2005

Syndax Pharmaceuticals, a Waltham-based biopharmaceutical company, specializes in cancer therapies.

Public · $803.6M107
Clovis OncologyClovis OncologyBoulder, CO, USCancer Treatmentsest. 2009Clovis OncologyBoulder, CO, US · est. 2009

Clovis Oncology, a global biotech firm, specializes in developing and commercializing cancer treatments.

Public · $145M413
Iterion Therapeutics
Iterion Therapeutics
Series B$21.4M142014Houston, TX, US
Founder

Leadership at Iterion Therapeutics

Rahul ArasRahul ArasCEO

Similar to Iterion Therapeutics

Civetta TherapeuticsCivetta TherapeuticsCambridge, MA, USCancer Treatmentsest. 2019Civetta TherapeuticsCambridge, MA, US · est. 2019

Civetta Therapeutics: Advancing cancer treatment through innovative small molecule interventions.

Series A · $53M39
Tvardi TherapeuticsTvardi TherapeuticsHouston, TX, USBiotechnology, Therapeuticsest. 2017Tvardi TherapeuticsHouston, TX, US · est. 2017

Tvardi Therapeutics: Pioneering breakthrough medicines for cancers and chronic diseases since 2017.

Series B · $81.4M20
EtiraRxEtiraRxDallas, TX, USCancer Treatmentest. 2018EtiraRxDallas, TX, US · est. 2018

EtiraRx: Pioneering breast cancer treatment through innovative research and novel therapeutics.

Series A · $9.9M9
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7

Sunil Sharma's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Sunil Sharma

Jonathan NorthrupJonathan NorthrupBoard Member · Stingray TherapeuticsDavid TingDavid TingCo-Founder · TellBioErica WeinsteinErica WeinsteinCo-Founder · LarondeTrinity BivalacquaTrinity BivalacquaCo-Founder · OncostingSunjay KaushalSunjay KaushalCo-Founder · NeoProgenSid SinhaSid SinhaCo-Founder · Intact Therapeutics